Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

被引：0
|
作者：
Hutchings, M. [1 ]
Morschhauser, F. [2 ]
Iacoboni, G. [3 ]
Carlo-Stella, C. [4 ]
Offner, F. C. [5 ]
Sureda, A. [6 ]
Salles, G. [7 ,8 ]
Martinez-Lopez, J. [9 ]
Crump, M. [10 ]
Lundberg, L. [11 ]
Dixon, M. [12 ]
Kwan, A. [13 ]
Wei, M. C. [13 ]
Broeske, A-M E. [14 ]
Carlile, D. [12 ]
O'Hear, C. [13 ]
Dickinson, M. J. [15 ,16 ]
机构：
[1] Rigshosp Copenhagen, Dept Oncol, Copenhagen, Denmark
[2] Ctr Hosp Reg Univ Lille, Lille, France
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Humanitas Univ, Milan, Italy
[5] Univ Ziekenhuis Gent, Ghent, Belgium
[6] Inst Catala Oncol Hospitalet, Barcelona, Spain
[7] Hosp Civils Lyon, Pierre Benite, France
[8] Univ Claude Bernard, Pierre Benite, France
[9] Hosp Univ 12 Octubre H12O, Madrid, Spain
[10] Princess Margaret Hosp, Toronto, ON, Canada
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Roche Prod Ltd, Welwyn Garden City, Herts, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Roche Pharma Res & Early Dev, Roche Innovat Ctr, Penzberg, Germany
[15] Royal Melbourne Hosp, Melbourne, Vic, Australia
[16] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226
引用
收藏
页码：58 / 59
页数：2
相关论文
共 50 条
  • [41] Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL).
    Henning, Jan-Willem
    Duan, Qiuli
    Bahlis, Nizar J.
    Daly, Andrew
    Duggan, Peter
    Shafey, Mona
    Stewart, Douglas Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] A DOSE-ESCALATION STUDY OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199/GDC-0199) PLUS BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN'S LYMPHOMA (NHL)
    de Vos, S.
    Flowers, C.
    Wang, D.
    Swinnen, L.
    Fowler, N.
    Reid, E.
    Cordero, J.
    Gifford, M.
    D'Amico, D.
    Dunbar, M.
    Zhu, M.
    Salem, A.
    Enschede, S. H.
    Ricker, J. L.
    Chien, D.
    Humerickhouse, R.
    Kozloff, M.
    HAEMATOLOGICA, 2015, 100 : 4 - 5
  • [43] Clofarabine (CLO) is active in patients (pts) with refractory and/or relapsed non-Hodgkin's lymphoma (NHL): A phase I/II study
    Nabhan, Chadi
    Fried, Walter
    Galvez, Angel G.
    Venugopal, Parameswaran
    Gozun, Phillip
    Bitran, Jacob D.
    BLOOD, 2007, 110 (11) : 186B - 186B
  • [44] Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing
    Djebli, Nassim
    Morcos, Peter N.
    Jaminion, Felix
    Guerini, Elena
    Kratochwil, Nicole A.
    Justies, Nicole
    Schick, Eginhard
    Kwan, Antonia
    Humphrey, Kathryn
    Lundberg, Linda
    Carlile, David
    BLOOD, 2020, 136
  • [45] Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
    Lamar, Zanetta S.
    Isom, Scott
    Vaidya, Rakhee
    Beaven, Anne W.
    McIver, Zachariah A.
    BLOOD, 2016, 128 (22)
  • [46] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Budde, Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen
    Kamdar, Manali
    Negricea, Raluca
    Song Pham
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
  • [47] The Therapeutic Response of Chidamide Was Associated with Elevated H3 Acetylation Level in Patients with Refractory/Relapsed Non-Hodgkin Lymphoma (R/R-NHL)
    Huang, Hui-Qiang
    Li, Pengfei
    Gao, Yan
    Bing, Bai
    Wang Xiaoxiao
    Rong Qixiang
    Li, Su
    Jiang, Wenqi
    BLOOD, 2017, 130
  • [48] A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Shouse, Geoffrey P.
    Blum, Kristie A.
    Haydu, Julie E.
    Abramson, Jeremy S.
    Narkhede, Mayur
    Ip, Andrew
    Michaelson, Jennifer S.
    Baeuerle, Patrick A.
    Meetze, Kristan
    Shapiro, Irina
    Shearer, Todd
    Inumerable, Judith
    Jones, Jeff
    Awan, Farrukh T.
    BLOOD, 2023, 142
  • [49] A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)
    Rossi, Giuseppe
    Prince, Henry Miles
    Tam, Constantine S.
    Ku, Matthew
    Thieblemont, Catherine
    Popplewell, Leslie L.
    Wermke, Martin
    Haioun, Corinne
    Doo, Nicole Wong
    Viardot, Andreas
    Ferreri, Andres J. M.
    Ferrari, Silvia
    Wong, Hansen L.
    Kadu, Priti
    Zugmaier, Gerhard
    Zeng, Yi
    Rambaldi, Alessandro
    BLOOD, 2021, 138
  • [50] Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F.
    Gonzalez de Villambrosia, S.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    De Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S4 - S4
12345